Compare Mesoblast Limited (MESO) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs T Rowe Price Group Inc — how do they compare? Mesoblast Limited trades at $14.13 (market cap $1.75B), while T Rowe Price Group Inc trades at $105.13 (market cap $22.23B). The key difference: T Rowe Price Group Inc is far larger — about 12.7× Mesoblast Limited's market cap, and T Rowe Price Group Inc pays a 4.99% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and T Rowe Price Group Inc for 115 Days on average.
| MESO | TROW | |
|---|---|---|
Market Cap | $1.75B | $22.23B |
Volume | 239,027 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $20.96 | $121.68 |
52-Week Low | $13.19 | $86.19 |
Typical Hold Time | 14 Days | 115 Days |
Enterprise Value | $1.83B | $19.43B |
Dividend Yield | — | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
T. Rowe Price Group (TROW) trades at $104.07, showing modest daily gains of 0.45%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a low P/E of 10.46 and robust profitability metrics. Recent earnings show two consecutive beats, with Q3 2026 results pending. The company maintains solid cash flow generation and recently announced a $1.30 dividend payment for September 2026, continuing its 40-year dividend growth streak.
TROW offers value characteristics with attractive valuation multiples and consistent dividend growth, though technical weakness and mixed analyst sentiment suggest near-term caution. Upside potential exists to the $112 consensus target, but investors face risks from market-sensitive revenue streams and ongoing net outflows despite AUM growth to $1.90 trillion as of August 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
